Vir Biotechnology doses first patient in VIR-5525 trial

Vir Biotechnology (VIR) announced that the first patient has been dosed in the company’s Phase 1 clinical trial evaluating VIR-5525, an investigational dual-masked T-cell engager targeting EGFR. VIR-5525 will be evaluated for the treatment of a variety of EGFR-expressing solid tumors in areas of high unmet need such as non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma.